Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Managing metastatic breast cancer and beyond using PARP inhibitors

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 158

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Dr Harold Burstein speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about PARP inhibitor use in patients with rare BRCA1/2 mutations.

He believes all patients should get tested, regardless of their BRCA1/2 mutational status to identify patients who might benefit from this type of therapy.

Dr Burstein then concludes by mentioning the potential use of PARP inhibitors in those who have a BRCA1/2 mutated pancreatic cancer.
 

This programme has been supported by an unrestricted educational grant from Pfizer.

Related videos

18.06.19

no rating
Cancer care in Latin America

follow us

Breast Cancer CDK 4/6


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation